Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study

The optimal management of fever in granulocytopenic patients remains controversial. This pilot study investigated the potential value of single daily doses of amikacin administered empirically with ceftriaxone in febrile granulocytopenic patients. None of the patients died as a result of infection o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1991-05, Vol.27 (suppl-C), p.129-139
Main Authors: Meunier, F., der Auwera, P. Van, Aoun, M., Ibrahim, S., Tulkens, P. M.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Agranulocytosis - complications
Amikacin - administration & dosage
Amikacin - adverse effects
Amikacin - blood
Amikacin - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial Infections - complications
Bacterial Infections - drug therapy
Biological and medical sciences
Ceftriaxone - administration & dosage
Ceftriaxone - adverse effects
Ceftriaxone - blood
Ceftriaxone - therapeutic use
Drug Administration Schedule
Drug Therapy, Combination - administration & dosage
Female
Hearing - drug effects
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pilot Projects
Vancomycin - adverse effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The optimal management of fever in granulocytopenic patients remains controversial. This pilot study investigated the potential value of single daily doses of amikacin administered empirically with ceftriaxone in febrile granulocytopenic patients. None of the patients died as a result of infection or toxicity from the prescribed regimen. Serum concentrations failed to show drug accumulation. Modifications of empirical antimicrobial therapy were made at a similar rate to other conventional regimens. Vancomycin seemed to increase the incidence of nephrotoxicity. Overall, this pilot study suggests that empirical therapy with single daily doses of amikacin plus ceftriaxone is safe and effective and should be further investigated in a larger number of patients.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/27.suppl_C.129